Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 49 (7), 864-872

Randomised Phase 3 Trial: Tegoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Esomeprazole in Patients With Erosive Oesophagitis

Affiliations

Randomised Phase 3 Trial: Tegoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Esomeprazole in Patients With Erosive Oesophagitis

Kwang Jae Lee et al. Aliment Pharmacol Ther.

Abstract

Background: Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders.

Aim: To confirm the non-inferiority of tegoprazan to esomeprazole in patients with erosive oesophagitis (EE).

Methods: In this multicentre, randomised, double-blind, parallel-group comparison study, 302 Korean patients with endoscopically confirmed EE (Los Angeles Classification Grades A-D) were randomly allocated to either tegoprazan (50 or 100 mg) or esomeprazole (40 mg) treatment groups for 4 or 8 weeks. The primary endpoint was the cumulative proportion of patients with healed EE confirmed by endoscopy up to 8 weeks from treatment initiation. Symptoms, safety and tolerability were also assessed.

Results: The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respectively. Both doses of tegoprazan were non-inferior to esomeprazole 40 mg. The incidence of adverse events was comparable among the groups, and tegoprazan was well-tolerated.

Conclusion: Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.

Figures

Figure 1
Figure 1
Randomisation protocol and patient disposition

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence‐based consensus. Am J Gastroenterol. 2006;101:1900‐1920. - PubMed
    1. Goh KL. Gastroesophageal reflux disease in Asia: a historical perspective and present challenges. J Gastroenterol Hepatol. 2011;26(Suppl. 1):2‐10. - PubMed
    1. El‐Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro‐oesophageal reflux disease: a systematic review. Gut. 2014;63:871‐880. - PMC - PubMed
    1. Hung LJ, Hsu PI, Yang CY, et al. Prevalence of gastroesophageal reflux disease in a general population in Taiwan. J Gastroenterol Hepatol. 2011;26:1164‐1168. - PubMed
    1. Kim KM, Cho YK, Bae SJ, et al. Prevalence of gastroesophageal reflux disease in Korea and associated health‐care utilization: a national population‐based study. J Gastroenterol Hepatol. 2012;27:741‐745. - PubMed

Publication types

Feedback